Fapon's Local Manufacturing Solutions at MEDICA 2026
Fapon, a leading entity in the biosciences field, is all set to participate in MEDICA 2026 from the 16th to the 19th of November in Düsseldorf, Germany. This year, the company will prominently showcase its innovative solutions aimed at bolstering local manufacturing capabilities and delivering reliable quality control materials for in vitro diagnostics (IVD).
Advancing Local Production
Fapon’s objective is to enhance the local production capacities of IVD manufacturers globally. Drawing on its extensive technological knowledge and industry experience, it aims to provide comprehensive support through seamless technology transfer and integrated diagnostic solutions. By focusing on local manufacturing, Fapon aims to adapt to the shifting needs of regional markets effectively.
At the MEDICA event, Fapon will highlight its
Local Manufacturing Solutions, which encompass a diverse array of diagnostic approaches, including Chemiluminescence Immunoassay (CLIA), ELISA, clinical biochemistry, Point-of-Care Tests (POCT), and Molecular Diagnostics (MDx). These offerings are designed to ease the transition to local production through adaptable cooperation models, ensuring a reliable supply of essential raw materials and reagents, bespoke development, manufacturing, and regulatory assistance.
Comprehensive IVD Solutions
In addition to localization services, Fapon will unveil its comprehensive IVD solutions portfolio. This includes raw materials, reagent services, and open system instruments. Their capabilities extend from antibody discovery and process development to reagent formulation and customization, empowering diagnostic manufacturers through each stage of product development and manufacturing.
A standout offering is Fapon’s blood-based test solution for Alzheimer’s Disease (AD), which provides essential biomarker materials in bulk quantities. These include p-Tau 217, p-Tau 181, Aβ40, Aβ42, GFAP, and NfL, all fundamental in aiding the development of blood-based assays for AD. By integrating both technical expertise and product support, Fapon enables partners to enhance and expand their diagnostic portfolios with flexibility.
Recombinant Quality Control Materials
An additional highlight will be Fapon’s recombinant materials for quality control (QC) and calibrators designed to ensure consistent testing outcomes and dependable supply chains. Utilizing recombinant expression technology mitigates supply variability and biosafety risks associated with natural-source materials, thereby guaranteeing high batch consistency.
In practical evaluations, the effectiveness of Fapon’s recombinant materials has been validated with impressive R² values, showcasing robust linearity and correlation in clinical performance assessments. Production can be tailored to client demands, with batch sizes ranging from 0.8 liters to 200 liters, ensuring reliability through quarterly production cycles and maintained inventory levels.
Furthermore, Fapon enhances its global supply capabilities through its Authorized Economic Operator (AEO) certification and overseas storage facilities. Its rich portfolio includes pivotal diagnostic markers such as RF, CRP, CK-MB, and ToRCH, supporting a wide variety of clinical applications in biochemistry, CLIA, ELISA, and POCT.
A Commitment to Innovation
With over 25 years of experience in the IVD sector, more than 1,400 patents, and partnerships across over 70 countries, Fapon remains committed to pushing the frontiers of innovation within diagnostic technologies and global collaborations. The company strives to expedite diagnostic development and reinforce local IVD manufacturing through its integrated technological expertise and extensive product lines.
Visitors are encouraged to connect with the Fapon team at Hall 3, Booth D95 during MEDICA 2026 to explore collaboration opportunities and learn more about their IVD solutions and services.
About Fapon
Fapon is a leading global life sciences enterprise redefining the R&D paradigm in diagnostics and therapeutics. The company adopts an innovative AI-driven model, significantly accelerating the discovery and implementation of novel biomarkers and therapeutic targets. Its comprehensive business structure integrates AI-supported research, one-stop diagnostic solutions, and innovative therapies, covering the entire healthcare management spectrum and advancing precision medicine development.
Follow Fapon on LinkedIn or visit their website at
faponbiotech.com for more information.